DOCSLIB.ORG

TUD Corporate-Design F"Ur Latex

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Salvinorin A Jomana Amro, Philipp Becker, Conny Büchner, Nad¨zaD¨zindo Contents 1 General Information 2 2 Historical Background 4 3 Synthesis 4 4 Eects 5 4.1 Working Principle . .5 4.2 Importance in Experimental Research . .5 4.3 Potential Medical Eects . .6 5 References 7 1 1 General Information1 Salvinorin A (SA) is a psychoactive neoclerodane diterpenoid isolated from the plant Salvia Divinorum, a member of the mint family that has historically been used in ethnomedical practices in Mexico2 and which has gained increased popularity as a recreational drug3. Characteristics of Salvinorin A Salvinorin A dierentiates to common hallucinogens in two ways. A common target of hallucinogens such as lysergic acid diethylamide (LSD) is the 5-HT2A serotonin receptor. However, Salvinorin A has no anity at 5-HT2A. The other dierence is structural. Classic hallucinogens are nitrogen compounds which Salvinorin A is not. IUPAC-Name methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2- (furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a- octahydro-1H-benzo[f] isochromene-7-carboxylate Chemical(Trivial) Names Salvinorin A Diviorin A 2H-Naphtho(2,1-c)pyran-7-carboxylic acid, 9-(acetyloxy)- 2-(3- furanyl)dodecahydro-6a,10b-dimethyl-4,10-dioxo-, methyl ester, (2S-(2alpha,4aalpha,6abeta,7beta,9beta, 10aalpha,10bbeta))- Molecular Formula C23H28O8 Molecular Weight 432.469 g/mol Melting Point 238-240°C Solubility in water 12.1 mg/L at 25°C Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 8 Isotope Atom Count 0 Dened Atom Stereocentre Count 7 Specic optional rotation -45.3 deg at 22 deg C/D ( c = 8.530 CHCl3) Hazard statements H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] Precautionary statements P264: Wash ... thoroughly after handling. P270: Do not eat, drink or smoke when using this product. P301+P312: If swallowed: Call a poison center or doctor/... if you feel unwell. P330: Rinse mouth. 1 https://pubchem.ncbi.nlm.nih.gov/compound/128563, 11.6.2019 2 Siebert 1994; Ott 1995; Ott 1996; Valdes et al. 2001 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208627/), 11.6.2019 3 Wu et al., 2011; Perron et al., 2012 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208627/), 11.6.2019 2 Salvia Divinorum Salvia Divinorum is also known as Diviner's Sage. There are about 900 dierent Salvia species including many ornamental garden sages and Salvia ocinalis, the common cooking sage. The plant has a charac- teristic weak 'mousy-but-minty' aroma. It originates from the south of Mexico, in the Sierra mazateca region in the mexican federal state Oaxaca.4 It is used by mazatec shamans and healers for rituals until today. In a low dose it is used for the therapy of physical inrmity and in a higher dose for visionary intoxication. The manners of consumption are very dierent: Mostly it is chewed, smoked or drunk as tea. It is used to get intoxicated around the world since the 1980`s. Nowadays Salvia Divinorum is illegal in many countries of the world. Salvinorin A Salvinorin A is found in the resin secreted by special, hairy epidermal cells (trichomes), which the leaves are especially abundant in. However, the actual Salvinorin A concentration of Salvia Divinorum products is generally unknown. Pure, crystalline Salvinorin A does not appear to be oered on markets (neither online or in smartshops) but illustrated procedures for its isolation are available on the Internet.5 Structure6 Salvinorin is a trans-neoclerodane diterpenoid and it is structurally distinct from other naturally occur- ring hallucinogens (such as DMT, psilocybin, and mescaline) because it contains no nitrogen therefore it is not an alkaloid and cannot be rendered as a salt. Salvinorin A has eight hydrogen-bond acceptor sites, all oxygen atoms, and no hydrogen-bond donor groups. It would thus appear likely that its crystal lattice should comprise only weak non-bonded inter- actions between adjacent molecules and a resultant diminished lattice energy reected in a low melting point. Figure 1: Structure 4 http://www.sagewisdom.org/faq.html, 11.6.2019 5 http://www.emcdda.europa.eu/publications/drug-proles/salvia, 11.6.2019 6 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4208627/, 11.6.2019 3 2 Historical Background7 The rst recorded mention of Salvia Divinorum was made in 1938 by Jean B. Johnson, who heard of Mazatecs making a tea from the leaves of hierba Maria, which induced visions in users. R. Gordon Wasson and Albert Hofmann acquired the rst specimen of Salvia Divinorum from the Mazatecs in 1962. They described it as a less desirable substitute for hallucinogenic mushrooms. Salvinorin A was rst named in 1982 by Alfredo Ortega and colleagues in Mexico. They used a combi- nation of spectroscopy and x-ray crystallography to determine the chemical structure of the compound, which was shown to have a bicyclic diterpene structure. Around the same time Leander Julián Valdés III independently isolated the molecule as part of his PhD research which was published in 1983. Valdés named the compound Divinorin and also isolated an analogue that he named Divinorin B. The naming was subsequently corrected to Salvinorin A and B after the work was published in 1984. Valdés later isolated Salvinorin C as well. 3 Synthesis8 Chemical Synthesis The synthesis of Salvinorin A is asymmetric and contains over 30 steps. It includes a transannular Michael reaction cascade and an intramolceluar Diels-Alder reaction/Tsuji allylation. Biosynthesis There are dierent theories on how Salvinorin A is biosynthesized. The most probable pathway is the 1-deoxy-d-xylulose-5-phosphate pathway, where D-glyceraldehyde 3-phosphate and pyruvate are transformed into D-xylulose 5-phosphate. After reduction it turns to 2C-methyl-D-erythritol 2,4- cyclodiphosphate, which then leads to the two base bodies isopentenyl diphosphate (IPP) and dimethy- lallyl diphosphate (DMAPP). Three IPPs are added to one DMAPP, which creates geranylgeranyl diphospate (GGPP). SdCPS2 catalyzes the next steps, where ent-clerodienyl diphosphate intermedi- ate is created. After oxygenation, acylation and methylation, the biosynthesis is completed. Figure 2: Biosynthesis of Salvinorin A 7 http://www.cesar.umd.edu/cesar/drugs/salvia.asp, 11.6.2019 8 Salvinorin A - Wikipedia, https://en.wikipedia.org/wiki/Salvinorin_A, 16.06.2019 4 4 Eects It was not until August 2002 that researchers discovered that Salvia Divinorum acts at the kappa opioid receptor (KOR) site, where much of human perception is regulated. This puts Salvia Divinorum in a class of drugs known as KOR agonists, which are thought to play psychotherapeutic roles in perception altering diseases such as schizophrenia and Alzheimer's disease. 4.1 Working Principle9 The kappa-opioid receptor is one of 3 G-protein linked opioid receptors which are often found in the nervous sytem. Opioid receptors consist of seven transmembrane comprehensive alpha helices proteins which are linked to inhibitory G-Proteins (guanosine triphosphate binding protein).10 An example for a natural agonist of KOR is dynorphine, while naloxone and naltrexone are examples for natural antagonists.11 In general a stimulation of KOR leads to analgesia (pain relief), dysphoria (trouble of emotions), miosis (contraction of the pupil) and sedation (reduction of the CNS funktion).12 G-proteins are linked loosly with the cytoplasmatic site of the membrane. If linked to GTP (guanosine triphosphate) they are activated and inactivated if they are linked to GDP (guanosine diphosphate). KOR is linked to an inactive G-protein.13 When KOR gets activated by signal molecules it changes its steric conformation. An inactivated, with GDP loaded G-protein links to KOR. This causes a substitution from GDP to GTP. The G-protein is now activated and dissociates from the receptor. It dissociates along the membrane and links to the eector protein adenylate cyclase. Thereby the eector changes its activity and stops catalyzing the formation of the second messenger cAMP (cyclic AMP) from ATP. This leads to an inhibition of the voltage controlled calcium channels whereby the calcium inux is reduced. Simultaneously potassium channels are opened. Potassium pours out of the cell. This leads to a hyperpolarisation. Thereby the neuronal signal transmission is inhibited.14 4.2 Importance in Experimental Research There is no approved medicinal use for Salvia Divinorum or Salvinorin A. However, there is intensive research to explore the therapeutic potential of structurally related KOR agonists or antagonists.15 Nonhuman research studies have characterized the pharmacological, behavioral, and discriminative ef- fects of S. divinorum and Salvinorin A17. There is interest in using Salvinorin A and related compounds to study kappa-opioid mechanisms in neurological disorders (e.g., Alzheimer's disease), psychiatric dis- orders, pain, and drug dependence18. Most information about the eects of Salvia Divinorum in humans has come from survey studies and qualitative interviews of Salvia Divinorum users. Survey respondents are in general agreement that the eects of Salvia Divinorum are intense and unique compared to other drugs or methods for inducing alterations in consciousness.19 9 https://www.spektrum.de/lexikon/neurowissenschaft/kappa-rezeptor/6390, 25.4.2019 10 http://geb.uni-giessen.de/geb/volltexte/2010/7621/pdf/DierkesBirgit_2010_04_28.pdf S.1-6, 2.5.2019 11 https://www.spektrum.de/lexikon/neurowissenschaft/opiatrezeptoren/9235, 25.4.2019 12 https://www.pharmacytimes.com/contributor/jerey-fudin/2018/01/opioid-agonists-partial-agonists-antagonists- oh-my, 30.4.2019 13 Biologie, Campbell, Reece; Pearson Studium; 8. aktualisierte Auage S. 280-285; 1127-1128 14 https://opus.bibliothek.uni-wuerzburg.de/opus4-wuerzburg/frontdoor/deliver/index/docId/5881/le/ DissertationNFfoLebensl.pdf S.1-8, 2.5.2019 15 http://www.emcdda.europa.eu/publications/drug-proles/salvia, 11.6.2019 17 Vortherms TA, Roth B:.
Recommended publications
  • American Civil Liberties Union

    American Civil Liberties Union

    WASHINGTON LEGISLATIVE OFFICE March 19, 2012 Honorable Patti B. Saris, Chair United States Sentencing Commission One Columbus Circle, N.E. Suite 2-500, South Lobby Washington, D.C. 2002-8002 Re: ACLU Comments on Proposed Amendments to Sentencing Guidelines, Policy Statements, and Commentary due on March 19, 2012 AMERICAN CIVIL LIBERTIES UNION WASHINGTON Dear Judge Saris: LEGISLATIVE OFFICE 915 15th STREET, NW, 6 TH FL WASHINGTON, DC 20005 With this letter the American Civil Liberties Union (“ACLU”) provides T/202.544.1681 commentary on the Amendments to the U.S. Sentencing Guidelines F/202.546.0738 WWW.ACLU.ORG (“Guidelines”) proposed by the Commission on January 19, 2012. The American Civil Liberties Union is a non-partisan organization with more than LAURA W. MURPHY DIRECTOR half a million members, countless additional activists and supporters, and 53 NATIONAL OFFICE affiliates nationwide dedicated to the principles of liberty, equality, and justice 125 BROAD STREET, 18 TH FL. embodied in our Constitution and our civil rights laws. NEW YORK, NY 10004-2400 T/212.549.2500 These comments address four issues that the Commission has asked for OFFICERS AND DIRECTORS SUSAN N. HERMAN public comment on by March 19, 2012. First, the ACLU encourages the PRESIDENT Commission to reject the adoption of the 500:1 MDMA marijuana equivalency ANTHONY D. ROMERO ratio for N-Benzylpiperazine, also known as BZP, (BZP) and make substantial EXECUTIVE DIRECTOR downward revisions to the MDMA marijuana equivalency ratio. Also, we urge ROBERT REMAR the Commission to respect the principles of proportionality and due process in TREASURER deciding how and whether to amend the Guideline for unlawfully entering or remaining in the country.
  • Programme & Abstracts

    Programme & Abstracts

    The 57th Annual Meeting of the International Association of Forensic Toxicologists. 2nd - 6th September 2019 BIRMINGHAM, UK The ICC Birmingham Broad Street, Birmingham B1 2EA Programme & Abstracts 1 Thank You to our Sponsors PlatinUm Gold Silver Bronze 2 3 Contents Welcome message 5 Committees 6 General information 7 iCC maps 8 exhibitors list 10 Exhibition Hall 11 Social Programme 14 opening Ceremony 15 Schedule 16 Oral Programme MONDAY 2 September 19 TUESDAY 3 September 21 THURSDAY 5 September 28 FRIDAY 6 September 35 vendor Seminars 42 Posters 46 oral abstracts 82 Poster abstracts 178 4 Welcome Message It is our great pleasure to welcome you to TIAFT Gala Dinner at the ICC on Friday evening. On the accompanying pages you will see a strong the UK for the 57th Annual Meeting of scientific agenda relevant to modern toxicology and we The International Association of Forensic thank all those who submitted an abstract and the Toxicologists Scientific Committees for making the scientific programme (TIAFT) between 2nd and 6th a success. Starting with a large Young Scientists September 2019. Symposium and Dr Yoo Memorial plenary lecture by Prof Tony Moffat on Monday, there are oral session topics in It has been decades since the Annual Meeting has taken Clinical & Post-Mortem Toxicology on Tuesday, place in the country where TIAFT was founded over 50 years Human Behaviour Toxicology & Drug-Facilitated Crime on ago. The meeting is supported by LTG (London Toxicology Thursday and Toxicology in Sport, New Innovations and Group) and the UKIAFT (UK & Ireland Association of Novel Research & Employment/Occupational Toxicology Forensic Toxicologists) and we thank all our exhibitors and on Friday.
  • HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do

    HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do

    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use MEMANTINE and DONEPEZIL ---------------------CONTRAINDICATIONS -------------------- HYDROCHLORIDES EXTENDED-RELEASE Memantine and donepezil hydrochlorides extended-release CAPSULES safely and effectively. See full prescribing capsules are contraindicated in patients with known information for MEMANTINE and DONEPEZIL hypersensitivity to memantine hydrochloride, donepezil HYDROCHLORIDES EXTENDED-RELEASE hydrochloride, piperidine derivatives, or to any excipients CAPSULES. used in the formulation. (4) MEMANTINE and DONEPEZIL HYDROCHLORIDES ------------------WARNINGS AND PRECAUTIONS ---------- extended-release capsules, for oral use • Memantine and donepezil hydrochlorides extended- Initial U.S. Approval: 2014 release is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia. (5.1) ------------------RECENT MAJOR CHANGES ----------------- • Memantine and donepezil hydrochlorides extended- Indications and Usage (1) 07/2016 release may have vagotonic effects on the sinoatrial and Dosage and Administration (2.1, 2.3) 07/2016 atrioventricular nodes manifesting as bradycardia or heart block. (5.2) ------------------INDICATIONS AND USAGE------------------ • Monitor patients for symptoms of active or occult Memantine and donepezil hydrochlorides extended-release gastrointestinal bleeding, especially those at increased capsules are a combination of memantine hydrochloride, an risk for developing ulcers. (5.3) NMDA receptor
  • Drug Education Student Booklet

    Drug Education Student Booklet

    WHAT YOU NEED TO KNOW STUDENT VERSION CONTENTS What is a drug? 3 How many young people use drugs and alcohol? 4 Drug and alcohol use and the law 6 Making choices 7 How to help a friend who has taken a drug 10 DRS-ABCD: Basic life support flow chart 13 Putting someone in the recovery position 14 How to help a friend or family member with their drug or alcohol use 15 Drugs A-Z Alcohol 17 Benzodiazepines 18 Cannabis 19 Cocaine 20 GHB 21 Hallucinogens 22 Heroin 23 Inhalants 24 Ketamine 25 MDMA/Ecstasy 26 Methamphetamine 27 New psychoactive substances 28 Synthetic cannabinoids 29 Performance and image-enhancing drugs 30 Tobacco & e-cigarettes 31 Polydrug use 32 Notes 33 Glossary 36 More information and sources of help 37 2 WHAT IS A DRUG? Drugs (including alcohol) are substances that affect the way the body functions when they are used. If a drug is illegal it means that it is forbidden by law. Different drugs have different effects on people, and different factors can impact on the experience of drug use. These include: ● the drug itself (e.g. the pharmacological properties of the substance being taken); ● the individual taking the drug (e.g. age, sex, physical and mental health of a person); ● the environment (the setting where the drug is being used, which can be legal, cultural or situational). Drinking two or three beers might be relatively low risk for a healthy adult but the risk of harm increases if they drink on an empty stomach, try to drive a car after drinking, or have a pre- existing health problem.
  • Psychoactive Substances and Transpersonal States

    Psychoactive Substances and Transpersonal States

    TRANSPERSONAL PSYCHOLOGY RESEARCH REVIEW: PSYCHOACTIVE SUBSTANCES AND TRANSPERSONAL STATES David Lukoff San Francisco, California Robert Zanger Los Angeles, California Francis Lu San Francisco, California This "Research Review" covers recent trends in researching psychoactive substances and trans personal states of conscious­ ness during the past ten years. In keeping with the stated goals of this section of the Journal to promote research in transpersonal psychology, the focus is on the methods and trends designs which are being employed in investigations rather than during the findings on this topic. However, some recently published the books and monographs provide good summaries of the recent last findings relevant to understanding psychoactive substances ten (Cohen & Krippner, 1985b; Dobkin de Rios, 1984;Dobkin de years Rios & Winkelman, 1989b; Ratsch, 1990; Reidlinger, 1990). Because researching psychoactive substances is most broadly a cross-disciplinary venture, only a small portion of the research reviewed below was conducted by persons who consider The authors wish to acknowledge the assistance of Bruce Flath, head librarian at the California Institute of Integral Studies, San Francisco in conducting the computer bibliographic searches used in preparation of this article. The authors also wish to thank Marlene Dobkin de Rios, Stanley Krippner, Christel Lukoff, Dennis McKenna, Terence McKenna, Ralph Metzner, Donald Rothberg and Ilene Serlin for their valuable comments on earlier drafts of this article. Copyright © 1990 Transpersonal Institute The Journal of Transpersonal Psychology. 1990, Vol. 22, No.2 107 themselves transpersonal psychologists. As Vaughan (1984) has noted, "The transpersonal perspective is a meta-perspec­ tive, an attempt to learn from all different disciplines . emerging from the needed integration of ancient wisdom and modern science.
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
  • Temporary Class Drug Order Report: 5-6APB and Nbome Compounds

    Temporary Class Drug Order Report: 5-6APB and Nbome Compounds

    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Rachel Fowler 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 0555 [email protected] Home Secretary Rt Hon. Theresa May MP Home Office 2 Marsham Street London SW1P 4DF 29 May 2013 Dear Home Secretary, I am writing to formally request that you consider laying a temporary class drug order (TCDO) pursuant to section 2A of the Misuse of Drugs Act 1971 on the following two groups of novel psychoactive substances (NPS). We consider the laying of TCDOs is appropriate as a pre-emptive measure in advance of the summer music festival season. Both classes of drugs have been associated with serious harm and drug-related deaths. ‘Benzofury’ compounds 5- and 6-APB and related substances are phenethylamine-type materials, related to ecstasy (MDMA). There have been several deaths and hospitalisations in the UK associated with these NPS, although poly-substance use often complicates the case. Research indicates that there is a potential risk of cardiac toxicity associated with the long-term use of 5- and 6-APB. Anecdotal user reports suggest that the consumption of these substances can cause insomnia, increased heart rate and anxiety, with some users reporting MDMA like symptoms. The related compound 5-IT has been subject to an EMCDDA-Europol joint report and an EMCDDA risk assessment exercise. [www.emcdda.europa.eu/publications/joint-reports/5- IT] 1 The substances recommended for control are: 5- and 6-APB: (1-(benzofuran-5-yl)-propan-2-amine and 1-(benzofuran-6-yl)-propan- 2-amine) and their N-methyl derivatives.
  • Journal of the House

    Journal of the House

    MAY 5, 2021 1305 Journal of the House SIXTY-SECOND DAY HALL OF THE HOUSE OF REPRESENTATIVES, TOPEKA, KS, Wednesday, May 5, 2021, 10:00 a.m. The House met pursuant to adjournment with Speaker Ryckman in the chair. The roll was called with 122 members present. Reps. Howard and Neighbor were excused on verified illness. Rep. Awerkamp was excused on excused absence by the Speaker. Excused later: Rep. Samsel. Prayer by Chaplain Brubaker: Loving and Merciful God, Thank You for the privilege of another day of life. Today I ask that You show mercy upon our leaders as they continue to face the many challenges. As they continue the pace of their schedules and juggle their obligations, help them to find their strength and encouragement in You. Help them to walk in Your light. May they place their trust in You and allow You to guide their decisions. Keep them in Your care, confident of Your watchfulness. We thank You for the way you are using them in working together on key decisions for our state. Continue to show mercy and grace to them. In Your Name I pray, Amen. The Pledge of Allegiance was led by Rep. Thompson. INTRODUCTION OF BILLS AND CONCURRENT RESOLUTIONS The following bill was introduced and read by title: HB 2454, AN ACT concerning crimes, punishment and criminal procedure; relating to the criminal discharge of a firearm; creating additional violations for discharges near a school and certain projectiles; amending K.S.A. 2020 Supp. 21-6308 and repealing the existing section, by Committee on Federal and State Affairs.
  • LSD), Which Produces Illicit Market in the USA

    LSD), Which Produces Illicit Market in the USA

    DEPENDENCE LIABILITY OF "NON-NARCOTIC 9 DRUGS 81 INDOLES The prototype drug in this subgroup (Table XVI) potentials. Ibogaine (S 212) has appeared in the is compound S 219, lysergide (LSD), which produces illicit market in the USA. dependence of the hallucinogen (LSD) type (see above). A tremendous literature on LSD exists which documents fully the dangers of abuse, which REFERENCES is now widespread in the USA, Canada, the United 304. Sandoz Pharmaceuticals Bibliography on Psychoto- Kingdom, Australia and many western European mimetics (1943-1966). Reprinted by the US countries (for references see Table XVI). LSD must Department of Health, Education, & Welfare, be judged as a very dangerous substance which has National Institute of Mental Health, Washington, no established therapeutic use. D.C. 305. Cerletti, A. (1958) In: Heim, R. & Wasson, G. R., Substances S 200-S 203, S 206, S 208, S 213-S 218 ed., Les champignons hallucinogenes du Mexique, and S 220-S 222 are isomers or congeners of LSD. pp. 268-271, Museum national d'Histoire natu- A number of these are much less potent than LSD in relle, Paris (Etude pharmacologique de la hallucinogenic effect or are not hallucinogenic at all psilocybine) (compounds S 203, S 213, S 216, S 217, S 220 and 306. Cohen, S. (1965) The beyond within. The LSD S 222) and accordingly carry a lesser degree of risk story. Atheneum, New York than LSD. None of these weak hallucinogens has 307. Cohen, S. & Ditman, K. S. (1963) Arch. gen. been abused. Other compounds are all sufficiently Psychiat., 8, 475 (Prolonged adverse reactions to potent to make it likely that they would be abused if lysergic acid diethylamide) 308.
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun

    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com

    Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com

    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
  • Eb07 REBIRTH-1.Pdf

    Eb07 REBIRTH-1.Pdf

    REBIRTH: The Psychedelic Movement Comes Of Age In the End I was cast out of the alchemists’ den, a lost mystic exile from the beats, wandering the naked streets of Basel at dawn and transmitting a lovely fix. I was high on acid, a green tab of Hofmann’s bicycle wheel I had rever- ently acquired from the Californian High Priest nights before, high in the hotel room overlooking the tram depot opposite the Basel Congress Centre. Site of the conference diabolique with Dr. Albert Hofmann, the 100 year old Alche- mist that birthed LSD - the ‘Problem Child’ that switched on the world. Now: cloudbanks are/ rolling/ blooming/ shifting overhead and as they open up and become for me everything else is doing the same – trees, cars, people - especially people. These beautiful marionette citizens of Basel, heading off to work, rugged up against the winter chill. They are polite, cool, efficiently progressing through the basic programs of larval life. Light glistens past a woman on the second floor balcony of an apartment block as she shakes out a blanket. Down below, surrounded by layers of white, white snow, a middle-aged man is walking his dog. He waits patiently, well trained, as it sniffs a pole. They are radiating energy signatures that overlap like kaleidoscope pictures and sink deep into me. You know this feeling, the current. A stream of energy is bubbling within you straight from the source, and the more you let go and let it rise up and blossom in/ from you, the deeper in you go.